Navigation Links
Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
Date:10/12/2010

The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells.

At the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Marianne Pavel from Charit University in Berlin, Germany reported that everolimus improved progression-free survival by 5.1 months in patients with advanced neuroendocrine tumors.

Neuroendocrine tumors are slow-growing malignancies that originate from cells of the body's neuroendocrine system. These cells are found throughout the body in organs such as the gastrointestinal tract and the lungs. The tumors are mostly non-responsive to chemotherapy drugs. They affect less than five people in 100,000, and until now there have been few treatment options for inhibition of tumor growth.

In the new RADIANT-2 trial, researchers in several European countries and the USA treated 429 patients with progressing, well- or moderately-differentiated advanced neuroendocrine tumors with either everolimus plus a somatostatin analog called octreotide LAR, or placebo plus octreotide LAR.

All patients had a history of 'carcinoid' symptoms, meaning the tumors have been secreting excessive levels of amines, especially serotonin, leading to symptoms such as flushing and diarrhea. The tumor originated in the small intestine in about 50% of patients.

Overall, the median progression-free survival for patients given everolimus plus octreotide LAR was 16.4 months, significantly longer than the median 11.3 months for placebo plus octreotide LAR, Dr Pavel reported.

"This is the first Phase-III trial of the combination therapy with octreotide LAR and everolimus and it is the largest trial that has ever been done in this type of neuroendocrine tumors," Dr Pavel said. "When we designed the study, we tested for an improvement of at least 4.5 months compared t
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Front-of-package symbols and systems: IOM phase 1 report
2. Vaccine extends glioblastoma patients survival in phase II trial
3. Operation Unified Response: 3 phases of disaster care in Haiti
4. Aeras and Crucell announce Phase II clinical trial start in Kenya
5. Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial
6. Mass. General Hospital, Iacocca Foundation announce completion of Phase I diabetes trial
7. Late-stage ovarian cancer shows promise in 2-drug phase I trial
8. Late-stage ovarian cancer shows promise in two-drug phase I trial
9. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
10. Phase II study of an oral therapy for Gaucher disease yields positive results
11. New phase II study supports potential of gs-9450 as new treatment option for steatohepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2015)... 18, 2015 PHOENIX, ARIZONA – In ... with 11 other secure destruction professionals across the United ... (CSDS). He will now display “CSDS” as a professional ... before the National Association of Information Destruction 2015 Annual ... Grapevine, Texas. Of the 20 people who took the ...
(Date:4/17/2015)... (PRWEB) April 18, 2015 Rosetta Radiology ... facility, rounding out their list of diagnostic imaging services. ... for patients on the Upper East Side of Manhattan. ... at full capacity. The addition of PET-CT, combined with ... physicians the ability to work with patients through several ...
(Date:4/17/2015)... April 17, 2015 Florida Hospital Wesley ... and Florida Hospital Carrollwood were all selected as Top ... located in Pasco County, is ranked number one for ... survey, which was conducted in partnership with an independent ... all-private bed hospital that opened in October of 2012 ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 Consumers who ... protection without modifications can now use the Insurance Pros ... life insurance policy rates that are featured by leading ... standard plans that are offered are mixed between three ... 18 to 79. There are now term, universal and ...
(Date:4/17/2015)... 2015 At the end of February ... the “Salute to the Oscars” in the Stardust Penthouse ... overlooking the impressive Los Angeles skyline. These events honoring ... Durkin, LA’s leading producer of sustainable product placement in ... world’s premier providers of eco-friendly and socially conscious products ...
Breaking Medicine News(10 mins):Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 2Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 3Health News:Tampa Bay Times Selects Florida Hospital Wesley Chapel, Florida Hospital at Connerton Long Term Acute Care and Florida Hospital Carrollwood As Top Workplaces in Tampa Bay 4Health News:General Life Insurance Policy Rates Added to Quotation System at Insurance Website Online 2Health News:Choices Recovery Speaks with Dakota Hood of “The Hunger Games” about Addiction in Hollywood 2
... It appears that stroke patients who receive both intravenous ... blood clots and endovascular interventions such as ... likely to recover and have lower chances of dying, ... Research Center at the University of Minnesota Medical School., ...
... documentary from Peabody-Award-winning filmmaker,Joseph Lovett - premieres December ... Trailer available at http://www.blooddetectives.org ., ... conjunction with the American Society of,Hematology (ASH) presents ... on December 19, 2008, at 7:00 PM ET/PT ...
... Puerto Rico and District of Columbia get failing grades , , ... premature birth rates, the United States rates a "D," and ... get failing grades. , That,s the sobering conclusion of the ... , released Wednesday. Not a single state earned an "A." ...
... TORRANCE, Calif., Nov. 12 A study published ... energy drinks can cause,caffeine intoxication. It suggested product ... intoxication include nausea, headache, heart,palpitations, insomnia, anxiety or ... comes from the high levels of caffeine,and sugar ...
... Cycling ... iPhone Apps, ... leader in indoor group cycling, today introduced,the new iSPINNING(TM) fitness application ... time only, is an innovative new,cardio and cycling application that compiles ...
... software MCT-Diabetes, has announced that nationally-recognized diabetes specialist Dr. Steven ... regularly scheduled online column to the MyCareTeam diabetes community. ... ... 2008 -- MyCareTeam, Inc., a leading vendor of Internet-based diabetes ...
Cached Medicine News:Health News:Dual treatment for stroke leads to improved recovery rates, reduced mortality 2Health News:Documentary Examining Deadly Blood Disorders and Lifesaving Research to Premiere on Discovery Health 2Health News:Documentary Examining Deadly Blood Disorders and Lifesaving Research to Premiere on Discovery Health 3Health News:U.S. Gets a 'D' for Preterm Birth Rates 2Health News:Study Calls for Labeling of Potentially Dangerous Energy Drinks 2Health News:Spinning(R) Announces First Heart Rate and Fitness Application for the iPhone(TM) and iPod(R) touch 2Health News:Spinning(R) Announces First Heart Rate and Fitness Application for the iPhone(TM) and iPod(R) touch 3Health News:Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community 2Health News:Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community 3
(Date:4/17/2015)... , Apr. 17, 2015 Research and Markets ... addition of the "Medical Device Outsourcing - ... offering. This report analyzes the worldwide ... by the following Device Categories: Class I, Class ... analyzed in the report Include - Radiology, Orthopedic, ...
(Date:4/17/2015)... 17, 2015  Trovagene, Inc., (NASDAQ:  TROV) a ... clinical data presented at the 2015 European Lung ... Cancer Monitoring ℠ (PCM) platform outperformed tissue ... EGFR T790M mutations in metastatic lung cancer ... T790M Mutation in Urinary Circulating Tumor DNA from ...
(Date:4/17/2015)... Apr. 17, 2015 Steven Rash , the ... and its operating subsidiary American Seed & Oil Company, ... to investors yesterday in New York City.  Mr. Rash,s ... The American Seed & Oil Company has recently announced ... Butter Hemp Seed Foods , the EpiVape , ...
Breaking Medicine Technology:Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 2Medical Device Outsourcing (Radiology, Orthopedic, Neurology, Cardiology, and Others) Market 2015 - Global Strategic Business Report 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 2Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 3Trovagene's Urinary ctDNA Assay Outperforms Tissue Biopsy in Clinical Study for the Detection of EGFR T790M Mutations in Metastatic Lung Cancer Patients 4American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 2American Seed & Oil Company Benchmarks its Consumer Product Development Strategy Against Proctor & Gamble 3
... Pa. , May 3 Unisys Corporation announced today ... information management (HIM) business to Molina Healthcare, Inc. for $135 ... , , ... solutions and business process outsourcing services to state governments for administering ...
... LONDON , May 3, 2010 The ... 2016, but,a familiar name, Pfizer, will still be the biggest seller of ... today,by EvaluatePharma, the premier provider of pharma and biotech analysis. , ... The cancer ...
Cached Medicine Technology:Unisys Completes Sale of Health Information Management Business 2Pfizer Reigns Supreme After Patent Cliff as Humira Kicks Avastin off Top Spot 2Pfizer Reigns Supreme After Patent Cliff as Humira Kicks Avastin off Top Spot 3Pfizer Reigns Supreme After Patent Cliff as Humira Kicks Avastin off Top Spot 4Pfizer Reigns Supreme After Patent Cliff as Humira Kicks Avastin off Top Spot 5
Galaxy IVUS Imaging System simplifies the process of intracardiac echo while delivering accurate, real-time diagnostic information in less time with less work. (Ultra ICE catheter compatible)...
The Duett Pro is simple, precise and efficient. Duett Pro sleeve hub is lightweight and ergonomic. A 'quick connect' feature provides a secure connection of the sleeve hub to the base during catheter...
... VasoSeal VHD was ... rapidly stop bleeding after ... and radiology procedures. It ... sealing device approved for ...
... was the first device ... after diagnostic and interventional ... It is a collagen-based ... for immediate sheath removal ...
Medicine Products: